In 2019, the market size of China's smoking cessation products was about 1200 billion yuan, accounting for 35% of the global market. There are few first-line smoking cessation drugs, and the generic drug varenicline fills the domestic gap.
The only domestic nicotine replacement therapy product approved for marketing in China was a nicotine sublingual tablet (trade name "Orfinib") from Beijing Chengji Pharmaceutical, which was listed on November 22, 2020. None of the nicotine patches/nicotine transdermal patches are available.